Cited by 287Cancer-related Molecular PathwaysEstrogen and related hormone effectsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner

Bond, Gareth L., Hirshfield, Kim M., Kirchhoff, Tomas, Alexe, Gabriella, Bond, Elisabeth E., Robins, Harlan, Bartel, Frank, Taubert, Helge, Wuerl, Peter, Hait, William, Toppmeyer, Deborah, Offit, Kenneth, Levine, Arnold J.·2006·Cancer Research

DOI 10.1158/0008-5472.can-06-0180

Open this paper in CoChat — free account

Abstract

The importance of the p53 stress response pathway in the suppression of tumor formation is well documented. In a previous report, a single nucleotide polymorphism (SNP309 T/G) was found in the promoter of the MDM2 gene resulting in higher levels of MDM2 RNA and protein and, consequently, in the attenuation of the p53 pathway both in vitro and in vivo. As the SNP309 locus is found in a region of the MDM2 promoter, which is regulated by hormonal signaling pathways, and the G-allele of SNP309 increases the affinity of a well-described cotranscriptional activator of nuclear hormone receptors (i.e., Sp1), the hypothesis that the SNP309 locus could alter the effects of hormones on tumorigenesis was tested in vivo in humans. Data obtained from patients with three different sporadic cancers, from four independent case studies, support this hypothesis, providing an example for the genetic basis of gender differences in cancer and showing that the genotype at a specific locus can affect how hormones, like estrogen, affect tumorigenesis in humans.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-0180

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Cancer Epidemiology and Prevention
Schottenfeld, D. (2006) · doi:10.1093/acprof:oso/9780195149616.001.0001 · Cited by 3,376
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Self-citation
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma
Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2003) · JAMA · doi:10.1001/jama.289.11.1421 · Cited by 579
Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology
M�ller, A. M. S., Ihorst, G., Mertelsmann, R. H., & Engelhardt, M. M. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0939-7 · Cited by 495
Steroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438
Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer
Li, C. I. (2003) · JAMA · doi:10.1001/jama.289.24.3254 · Cited by 415
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G. L., Hu, W., & Levine, A. J. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 310
Self-citation
Multistep carcinogenesis of breast cancer and tumour heterogeneity
Beckmann, M. W., Niederacher, D., Schnürch, H.-G., Gusterson, B. A., & Bender, H. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050128 · Cited by 301
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome
Bougeard, G., Baert-Desurmont, S., Tournier, I., Vasseur, S., Martin, C., Brugières, L., Chompret, A., Paillerets, B. B., Stoppa‐Lyonnet, D., Bonaïti‐Pellié, C., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.037952 · Cited by 216
A Single Nucleotide Polymorphism in the MDM2 Gene: From a Molecular and Cellular Explanation to Clinical Effect
Bond, G. L., Hu, W., & Levine, A. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0825 · Cited by 176
Self-citation
The Role ofP53andMDM2Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma
Yuan, H., Miao, X., Zhang, X., Ding, F., Luo, A., Guo, Y., Tan, W., Liu, Z., & Lin, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1460 · Cited by 173
Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression
Kinyamu, H. K., & Archer, T. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5867-5881.2003 · Cited by 157
Genetic polymorphisms in cell cycle regulatory genesMDM2 andTP53 are associated with susceptibility to lung cancer
Zhang, X., Miao, X., Guo, Y., Tan, W., Zhou, Y., Sun, T., Wang, Y., & Lin, D. (2005) · Human Mutation · doi:10.1002/humu.20277 · Cited by 156
Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor α and SP proteins
Stoner, M. A., Wormke, M., Saville, B., Samudio, I. J., Qin, C., Abdelrahim, M., & Safe, S. H. (2003) · Oncogene · doi:10.1038/sj.onc.1207201 · Cited by 147
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer
Lind, H., Zienolddiny, S., Ekstrøm, P. O., Skaug, V., & Haugen, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21872 · Cited by 144
Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites
Petz, L. N., Ziegler, Y., Schultz, J. R., Kim, H., Kemper, J. K., & Nardulli, A. M. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2003.11.008 · Cited by 142
Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County.
Bernstein, L., & Ross, R. (1992) · PubMed · Cited by 134
Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma
Chen, W. Y., Hankinson, S. E., Schnitt, S. J., ROSNER, B. A., Holmes, M. D., & Colditz, G. A. (2004) · Cancer · doi:10.1002/cncr.20499 · Cited by 133
The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.
Sheikh, M. S., Shao, Z. M., Hussain, A., & Fontana, J. A. (1993) · PubMed · Cited by 127
Recommendations on Predictive Testing for Germ Line p53 Mutations Among Cancer-Prone Individuals
Li, F. P., Garber, J. E., Friend, S. H., Strong, L. C., Patenaude, A. F., Juengst, E. T., Reilly, P. R., Correa, P., & Fraumeni, J. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.15.1156 · Cited by 126
A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells
Arva, N. C., Gopen, T., Talbott, K. E., Campbell, L. E., Chicas, A., White, D. E., Bond, G. L., Levine, A. J., & Bargonetti, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505203200 · Cited by 122
Self-citation
Association Between MDM2–SNP309 and Age at Colorectal Cancer Diagnosis According to p53 Mutation Status
Menin, C., Scaini, M. C., Salvo, G. L. D., Biscuola, M., Quaggio, M., Esposito, G., Belluco, C., Montagna, M., Agata, S., D’Andrea, E., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj054 · Cited by 121
Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review
Dietel, M., Lewis, M. A., & Shapiro, S. (2005) · Human Reproduction · doi:10.1093/humrep/dei043 · Cited by 114
The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck
Alhopuro, P., Ylisaukko‐oja, S. K., Koskinen, W. J., Bono, P., Arola, J., Järvinen, H. J., Mecklin, J., Atula, T. S., Kontio, R., Mäkitie, A. A., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.031260 · Cited by 114
p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps, M., Darley, M., Primrose, J. N., & Blaydes, J. P. (2003) · PubMed · Cited by 109
Abnormal expression of MDM-2 in breast carcinomas
Bueso-Ramos, C., Manshouri, T., Haidar, M. A., Yang, Y. S., McCown, P., Ordóǹez, N. G., Glassman, A. B., Sneige, N., & Albitar, M. X. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806499 · Cited by 103
mdm2 gene alterations and mdm2 protein expression in breast carcinomas
Marchetti, A., Buttitta, F., Girlando, S., Palma, P. D., Pellegrini, S., Fina, P., Doglioni, C., Bevilacqua, G., & Barbareschi, M. (1995) · The Journal of Pathology · doi:10.1002/path.1711750106 · Cited by 103
Improving cancer therapy by non-genotoxic activation of p53
Laı́n, S., & Lane, D. P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00063-7 · Cited by 99
Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frébourg, T., Kassel, J., Lam, K. T., Gryka, M. A., Barbier, N., Andersen, T. I., Børresen‐Dale, A., & Friend, S. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6413 · Cited by 97
Estrogen Receptor/Sp1 Complexes Are Required for Induction ofcadGene Expression by 17β-Estradiol in Breast Cancer Cells
Khan, S., Abdelrahim, M., Samudio, I. J., & Safe, S. H. (2003) · Endocrinology · doi:10.1210/en.2002-0149 · Cited by 96
The New York Cancer Project: Rationale, Organization, Design, and Baseline Characteristics
Mitchell, M. K. (2004) · Journal of Heredity · doi:10.1093/jurban/jth116 · Cited by 91
Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines
Danel, L., Menouni, M., Cohen, J. H. M., Magaud, J., Lenoir, G., Revillard, J., & Saez, S. (1985) · Leukemia Research · doi:10.1016/0145-2126(85)90125-0 · Cited by 79
Reproductive Factors and Risk of Intermediate- or High-Grade B-Cell Non-Hodgkin’s Lymphoma in Women
Nelson, R. A., Levine, A. M., & Bernstein, L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1381 · Cited by 76
Self-citation
Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.
Gudas, J. M., Nguyen, H., Klein, R. C., Katayose, D., Seth, P. K., & Cowan, K. H. (1995) · PubMed · Cited by 74
Regulation of the mdm2 Oncogene by Thyroid Hormone Receptor
Qi, J.-S., Yuan, Y., Desai-Yajnik, V., & Samuels, H. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.864 · Cited by 65
Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx
Obata, A., Eura, M., Sasaki, J., Saya, H., Chikamatsu, K., Tada, M., Iggo, R. D., & Yumoto, E. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2 · Cited by 58
The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma
Hồng, Miao, M., Xp, Zhang, Xm, Ding, Luo, Guo, Yl, Tan, �., et al. (2006) · 中国生物学文摘 · Cited by 49
Presence of steroid receptors in human soft tissue sarcomas of diverse histological origin.
Chaudhuri, P. K., Walker, M. J., Beattie, C. W., & Gupta, T. K. D. (1980) · PubMed · Cited by 48
Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.
Cerhan, J. R., Vachon, C. M., Habermann, T. M., Ansell, S. M., Witzig, T. E., Kurtin, P. J., Janney, C. A., Zheng, W., Potter, J. D., Sellers, T. A., et al. (2002) · PubMed · Cited by 48
Sex steroid receptors in diverse human tumors.
Kobayashi, S., Mizuno, T., Tobioka, N., 市村, 秀., 佐本, 常., Tanaka, H., Masaoka, A., Wakabayashi, S., Umemura, S., Fukuoka, H., et al. (1982) · PubMed · Cited by 36
Distribution of steroid hormone receptors in human soft tissue sarcomas.
Pk, C., Walker, M. J., Cw, B., & Gupta, T. K. D. (1981) · PubMed · Cited by 34
MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia
Swinney, R. M., Hsu, S., Hirschman, B. A., Chen, T. T.-C., & Tomlinson, G. E. (2005) · Leukemia · doi:10.1038/sj.leu.2403941 · Cited by 30
Distinct promoter usage of mdm2 gene in human breast cancer
Okumura, N., Saji, S., Eguchi, H., Nakashima, S., Saji, S., & Hayashi, S. (2002) · Oncology Reports · doi:10.3892/or.9.3.557 · Cited by 28
Immunological detection of the oestradiol receptor protein in cell lines derived from the lymphatic system and the haematopoietic system: variability of specific hormone binding in vitro
Jakob, F. J., Tony, H. P., Schneider, D., & Thole, H. H. (1992) · Journal of Endocrinology · doi:10.1677/joe.0.1340397 · Cited by 19
Expression of estrogen receptors α and β in soft tissue sarcomas: Immunohistochemical and molecular analysis
Li, X., Hisaoka, M., & Hashimoto, H. (2003) · Pathology International · doi:10.1046/j.1440-1827.2003.01543.x · Cited by 18
Immunohistochemical study of steroid hormones and an estrogen binding assay in malignant soft tissue tumors.
Suda, A., Sato, T., Watanabe, Y., Yamakawa, M., & Imai, Y. (1990) · PubMed · Cited by 7

Sorted by citations

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
The genetics of the p53 pathway, apoptosis and cancer therapy
Vázquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 686
Self-citation
p53 polymorphisms: cancer implications
Whibley, C., Pharoah, P. D. P., & Hollstein, M. C. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2584 · Cited by 677
Li-Fraumeni Syndrome
Malkin, D. M. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 529
Gender Differences in Cancer Susceptibility: An Inadequately Addressed Issue
Dorak, M. T., & Karpuzoglu, E. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00268 · Cited by 505

See all 287

Authors: Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., Toppmeyer, D., Offit, K., & Levine, A. J.
Affiliations: Institute for Advanced Study (US)
Rutgers Cancer Institute (US)
Memorial Sloan Kettering Cancer Center (US)
Martin Luther University Halle-Wittenberg (DE)
Universität Ulm (DE)
ORCID: Bond, Gareth L.
Hirshfield, Kim M.
Kirchhoff, Tomas
Robins, Harlan
Taubert, Helge
Toppmeyer, Deborah
Offit, Kenneth
Levine, Arnold J.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2006-05-15
Volume: 66
Issue: 10
Pages: 5104-5110
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-06-0180
OpenAlex: W2131732631
Cited by: 287
References: 50
Citations by year: 2026: 1 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 21 · 2013: 17 · 2012: 24
FWCI: 18.09
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01 CA 65930-08, P01CA087497, P01CA065930, P01CA87497., T32CA099946, T32 CA 99946-01)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: MDM2, SNP309, promoter polymorphism, p53 pathway, tumor formation, gender differences in cancer, estrogen, Sp1, nuclear receptors, sporadic cancer, genetic susceptibility
MeSH terms: Adolescent, Adult, Age Factors, Aged, Alleles, Breast Neoplasms, Female, Humans, Male, Middle Aged, Neoplasms, Hormone-Dependent, Sarcoma, Case-Control Studies, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Ductal, Breast, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks